Accelerated Medicines Partnership
The Arthritis Foundation is part of an exciting new initiative, the Accelerating Medicines Partnership (AMP). AMP is a new venture that brings together the Foundation for the National Institutes of Health (FNIH), the National Institute of Health (NIH), 10 bio pharmaceutical companies and several non-profit organizations to work toward a common goal of earlier drug discovery and development for diseases, including rheumatoid arthritis and lupus.
As part of this cross-sector partnership, we will be able to share expertise and resources in a way that enables the best informed contributions to science. One critical component of this partnership is that industry partners will make the data and analysis resulting from AMP available to the broader bio-medical community.
The first pilot projects will begin in three disease areas:
- Alzheimer’s Disease
- type 2 diabetes
- autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus)
The pilot projects will be three to five years in length and aimed at characterizing effective molecular indicators of disease called biomarkers and distinguishing biological targets most likely to respond to new therapies. For more information about AMP, click here.